Asthma, House Dust Mite Allergy
Conditions
Brief summary
The purpose of this study is to investigate the safety of different doses of sublingual tablets of house dust mite allergen extracts in adults with house dust mite-associated allergic asthma.
Interventions
BIOLOGICALSLIT tablets of house dust mite allergen extracts
10 dosing days
BIOLOGICALMatching placebo
10 dosing days
Sponsors
Stallergenes Greer
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
* Written informed consent. * Male or female patient from 18 to 50 years. * Diagnosed asthma with medical history consistent with HDM-induced allergic asthma. * Positive SPT to House Dust Mites(HDM)and HDM-specific IgE serum value ≥ 0.7 kU/L. * Stable asthma treatments. * Spirometry with best FEV1 \> 70% of the predicted value. * Spirometry with reversibility of FEV1 of ≥ 12% and ≥ 200 mL. * Asthma Control Test™ (ACT) score ≥ 20.
Exclusion criteria
* Current smoker or former smoker with \> 10 pack/year history. * Co-sensitisation to any allergen possibly leading to clinically relevant respiratory allergy likely to significantly change the symptoms of the patient throughout the treatment period. * Patient with a past or current disease, which as judged by the Investigator, may affect the patient's participation in or the outcome of this study. * Patient with any oral condition that could confound the safety assessments or planning to have a dental extraction during the study. * Female patient pregnant or breast-feeding/lactating. * Female patient of childbearing potential not using a medically accepted contraceptive method. * Patient treated with beta-blockers, tricyclic antidepressants or monoamine oxidase inhibitors (MAOIs). * Patient who received allergen immunotherapy for HDM in the last 10 years. * Ongoing treatment by immunotherapy with another allergen.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety, tolerability as indicated by adverse events and safety laboratory evaluation | 10 dosing days |
Countries
France
Outcome results
None listed